Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by ITM Isotope Technologies Munich SE

ITM Appoints Dr. Celine Wilke as Chief Medical Officer
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Announces Updates to Commercial Leadership
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Presents Positive Topline Phase 3 COMPETE Trial Data with n.c.a. 177Lu-edotreotide (ITM-11), a Targeted Radiopharmaceutical Therapy, in Patients with Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors at the ENETS 2025 Conference
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM to Present Top Line Results from Phase 3 COMPETE Trial with [177Lu]Lu-edotreotide for the Treatment of Grade 1 & Grade 2 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at European Neuroendocrine Tumor Society (ENETS) Conference
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM to Present at Raymond James Private Biotech Symposium
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Announces Positive Topline Results of Phase 3 COMPETE Trial with ITM-11, a Targeted Radiopharmaceutical Therapy, in Patients with Grade 1 or Grade 2 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM and Ariceum Therapeutics Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM to Participate in Upcoming Investor Conferences
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM, TUM, and TUM University Hospital Sign New Framework Agreement to Advance Innovative Radiopharmaceutical Cancer Treatments
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM and NTP Strengthen Global Radioisotope Production Capacities by Renewing their Technology License Agreement and Signing a Manufacturing and Supply Agreement for n.c.a. Lutetium-177
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM to Present at Upcoming Radiopharmaceutical Investor Conferences in New York City
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Appoints Dr. Andrew Cavey as CEO to Lead Organization in its Next Stage of Growth
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Appoints Dr. Danielle Meyrick as Chief Medical Officer
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs Targeting Solid Tumors
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM, Helmholtz Munich and University Hospital Münster Announce First Patient Dosed in Phase I Investigator-Initiated Glioblastoma Trial
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Raises €188m to Enhance Radiopharmaceutical Pipeline and to Strengthen Leading Position in Medical Radioisotope Manufacturing
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Obtains Manufacturing License in the U.S.
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM and Alpha-9 Oncology Announce Global Supply Agreement to Support Alpha-9’s Clinical Radiopharmaceutical Development Program
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Announces Operational Readiness for NOVA Facility, the World’s Largest Lutetium-177 Production Site
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Appoints Dr. Mark Harfensteller as Member of its Executive Board
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development and Commercialization of Folate-Based Radiotheranostics
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Reports on Participation at 3rd ICPO Forum for Theranostics in Precision Oncology and Announces Support for ICPO Academy for Theranostics
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM to Host Theranostics Symposium on Clinical Need and Supply at SNMMI Annual Meeting on Sunday, June 25, 2023
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Opens World's Largest Lutetium-177 Production Facility for Targeted Radionuclide Therapies Against Cancer
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Announces €255m Investment Round, Plans to Advance Radiopharmaceutical Pipeline and to Expand Radioisotope Production Capacities
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
ITM Enters Cooperation Agreement with Paul Scherrer Institute (PSI) for Co-Development and Upscaled Manufacturing of Terbium-161 for Theranostic Application in Cancer
From ITM Isotope Technologies Munich SE
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.